Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 05, 2015 3:22 AM ET

Pharmaceuticals

Company Overview of Cerecor Inc.

Company Overview

Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406...

400 East Pratt Street

Suite 606

Baltimore, MD 21202

United States

Founded in 2011

11 Employees

Phone:

410-522-8707

Key Executives for Cerecor Inc.

Co-Founder,Chief Executive Officer, President and Director
Founder, Vice Chairman and Member of Nominating & Corporate Governance Committee
Age: 65
Founder and Chairman of Scientific Advisory Board
Age: 76
Founder and Member of Scientific Advisory Board
Age: 50
Interim Chief Financial Officer
Age: 47
Compensation as of Fiscal Year 2015.

Cerecor Inc. Key Developments

Cerecor Inc. Initiates Phase 2 Study for CERC-301

Cerecor Inc. announced that it has dosed the first subject in Clin301-203, a Phase 2 study of CERC-301 as an oral, adjunctive treatment of major depressive disorder (MDD). CERC-301 is an NR2B specific, NMDA antagonist, which the Company believes has the potential to provide a rapid onset of antidepressant effect. Clin301-203 is a randomized, double blinded placebo-controlled trial designed to evaluate the antidepressant effect of 12 mg and 20 mg doses of CERC-301. The trial is expected to enroll approximately 104 subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with either a serotonin reuptake inhibitor, or SSRI, or serotonin norepinephrine reuptake inhibitor, or SNRI. Clin301-203 includes two intermittent dose administrations seven days apart, followed by 14 days of observation. The primary objective of Clin301-203 is to evaluate the antidepressant effect of CERC-301, in 12 mg and 20 mg dosages, compared to placebo as assessed by the 6-item unidimensional sub-set of the Hamilton Depression Rating Scale.

Cerecor Eyes Acquisitions

Cerecor, Inc. is looking for acquisitions. The company has filed an IPO in the amount of $31.63 million. They intend to use the net proceeds from this offering, together with their existing cash and cash equivalents, to fund the costs of Phase 2 clinical development of CERC-301 and CERC-501, preclinical research for CERC-406, research and development to build their COMTi platform and potential in licensing or other acquisitions and for working capital and general corporate purposes.

Cerecor, Inc. Auditor Raises 'Going Concern' Doubt

Cerecor, Inc. filed its Annual on Jun 12, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
Verne Mendel Medical Corporation United States
Hoechst Marion Roussel Inc. United States
Cerep Inc. United States
Drug Royalty Trust 3 United States
Housey Pharmaceutical Research Laboratories LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cerecor Inc., please visit www.cerecor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.